The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis
Open accessAbstract
BACKGROUND: Treatment for hepatitis C virus (HCV) can lead to sustained virological response (SVR) in over 90% of people. Subsequent recurrence of HCV, either from late relapse or reinfection, reverses the beneficial effects of SVR. METHODS: A search identified studies analysing HCV recurrence post-SVR. The recurrence rate for each study was calculated using events/person years of follow-up (PYFU). Results were pooled using a random-effects model and used to calculate 5-year recurrence risk. Three patient groups were analysed: (1) Mono-HCV infected "low-risk" patients; (2) Mono-HCV infected "high-risk" patients (injecting drug users or prisoners); (3) human immunodeficiency virus (HIV)/HCV coinfected patients. Recurrence was defined as confirmed HCV RNA detectability post-SVR. RESULTS: In the 43 studies of HCV mono-infected "low-risk" patients (n = 7969) the pooled recurrence rate was 1.85/1000 PYFU (95% confidence interval [CI], .71-3.35; I(2) = 73%) leading to a summary 5-year recurrence risk of 0.95% (95% CI, .35%-1.69%). For the 14 studies of HCV monoinfected "high-risk" patients (n = 771) the pooled recurrence rate was 22.32/1000 PYFU (95% CI, 13.07-33.46; I(2) = 27%) leading to a summary 5-year risk of 10.67% (95% CI, 6.38%-15.66%). For the 4 studies of HIV/HCV coinfected patients the pooled recurrence rate was 32.02/1000 PYFU (95% CI, .00-123.49; I(2) = 96%) leading to a summary 5-year risk of 15.02% (95% CI, .00%-48.26%). The higher pooled estimates of recurrence in the high-risk and coinfected cohorts were driven by an increase in reinfection rather than late relapse. CONCLUSIONS: SVR appears durable in the majority of patients at 5 years post-treatment. The large difference in 5 year event rate by risk group is driven mainly by an increased reinfection risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Global epidemiology of hepatitis C virus infection
Shepard, C. W., Finelli, L., & Alter, M. J. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70216-4 · Cited by 2,758
Mohd Hanafiah, K., Groeger, J., Flaxman, A. D., & Wiersma, S. T. (2013) · Hepatology · doi:10.1002/hep.26141 · Cited by 2,515
Metaprop: a Stata command to perform meta-analysis of binomial data
Nyaga, V. N., Arbyn, M., & Aerts, M. (2014) · Archives of Public Health · doi:10.1186/2049-3258-72-39 · Cited by 2,139
Schaff, Z., & Csmos, G. (1994) · Cited by 1,868
Nelson, P. K., Mathers, B. M., Cowie, B., Hagan, H., Des Jarlais, D., Horyniak, D., & Degenhardt, L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61097-0 · Cited by 1,267
Torriani, F. J., Rodriguez-Torres, M., Rockstroh, J. K., Lissen, E., Gonzalez-García, J., Lazzarin, A., Carosi, G., Sasadeusz, J., Katlama, C., Montaner, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040842 · Cited by 1,233
Thein, H., Yi, Q., Dore, G. J., & Krahn, M. D. (2008) · Hepatology · doi:10.1002/hep.22375 · Cited by 829
Prognosis research strategy (PROGRESS) 1: A framework for researching clinical outcomes
Hemingway, H., Croft, P., Perel, P., Hayden, J. A., Abrams, K., Timmis, A., Briggs, A., Udumyan, R., Moons, K. G. M., Steyerberg, E. W., et al. (2013) · BMJ · doi:10.1136/bmj.e5595 · Cited by 663
Self-citationGerlach, J. T., Diepolder, H. M., Zachoval, R., Gruener, N. H., Jung, M.-C., Ulsenheimer, A., Schraut, W. W., Schirren, C. A., Waechtler, M., Backmund, M., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00668-1 · Cited by 524
Outcome of Sustained Virological Responders With Histologically Advanced Chronic Hepatitis C†,‡,§,¶
Morgan, T. R., Ghany, M. G., Kim, H.-Y., Snow, K. K., Shiffman, M. L., De Santo, J. L., Lee, W. M., Di Bisceglie, A. M., Bonkovsky, H. L., Dienstag, J. L., et al. (2010) · Hepatology · doi:10.1002/hep.23744 · Cited by 479
Webster, D. P., Klenerman, P., & Dusheiko, G. M. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62401-6 · Cited by 439
George, S. L., Bacon, B. R., Brunt, E. M., Mihindukulasuriya, K. L., Hoffmann, J., & Di Bisceglie, A. M. (2009) · Hepatology · doi:10.1002/hep.22694 · Cited by 399
Swain, M. G., Lai, M., Shiffman, M. L., Cooksley, W. G. E., Zeuzem, S., Dieterich, D. T., Abergel, A., Pessôa, M. G., Lin, A., Tietz, A., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.07.009 · Cited by 328
Eradication of Hepatitis C Virus in Patients Successfully Treated for Chronic Hepatitis C
Maylin, S., Martinot–Peignoux, M., Moucari, R., Boyer, N., Ripault, M., Cazals–Hatem, D., Giuily, N., Castelnau, C., Cardoso, A. C., Asselah, T., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.05.044 · Cited by 321
Historical epidemiology of hepatitis C virus (HCV) in selected countries
Bruggmann, P., Berg, T., Øvrehus, A. L. H., Moreno, C., Brandão Mello, C. E., Roudot‐Thoraval, F., Marinho, R. T., Sherman, M., Ryder, S. D., Sperl, J., et al. (2014) · Journal of Viral Hepatitis · doi:10.1111/jvh.12247 · Cited by 261
Pearlman, B. L., & Traub, N. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir076 · Cited by 261
Simmons, B., Saleem, J., Heath, K., Cooke, G. S., & Hill, A. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ396 · Cited by 261
Self-citationRücker, G., Schwarzer, G., Carpenter, J., & Olkin, I. (2009) · Statistics in Medicine · doi:10.1002/sim.3511 · Cited by 252
Veldt, B. J., Saracco, G., Boyer, N., Cammà, C., Bellobuono, A., Hopf, U., Castillo, I., Weiland, O., Nevens, F., Hansen, B. E., et al. (2004) · Gut · doi:10.1136/gut.2003.038257 · Cited by 174
Lemoine, M., Nayagam, S., & Thursz, M. R. (2013) · Future Virology · doi:10.2217/fvl.13.11 · Cited by 158
Rutter, K., Hofer, H., Beinhardt, S., Dulic, M., Gschwantler, M., Maieron, A., Laferl, H., Stättermayer, A. F., Scherzer, T. M., Straßl, R. P., et al. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12350 · Cited by 31
Hara, K., Rivera, M. M., Koh, C., et al. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit541 · Cited by 30
Yu, M., Dai, C., Chen, S., Lee, L., Hsieh, M., Lin, Z., Hsieh, M., Wang, L., Tsai, J., Chang, W., et al. (2005) · BMC Infectious Diseases · doi:10.1186/1471-2334-5-27 · Cited by 26
Cited by
EASL Recommendations on Treatment of Hepatitis C 2018
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.026 · Cited by 2,827
EASL recommendations on treatment of hepatitis C: Final update of the series☆
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.018 · Cited by 1,252
Ghany, M. G., Morgan, T. R., & Panel, A. H. C. G. (2020) · Hepatology · doi:10.1002/hep.31060 · Cited by 955
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
Cooke, G. S., Andrieux-Meyer, I., Applegate, T. L., Atun, R., Burry, J. R., Cheinquer, H., Dusheiko, G., Feld, J. J., Gore, C., Griswold, M. G., et al. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30270-x · Cited by 535
Self-citationBhattacharya, D., Aronsohn, A., Price, J., Lo Re, V., the American Association for the Study of Liver Diseases–Infectious Diseases Society of America HCV Guidance Panel, Heald, J., Demisashi, G., Durzy, E., Davis-Owino, A., & Tynes, S. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad319 · Cited by 296
Metadata
- Authors
- Simmons, B., Saleem, J., Hill, A., Riley, R. D., & Cooke, G. S.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-01-19
- Volume
- 62
- Issue
- 6
- Pages
- 683-694
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2274680380
- Cited by
- 314
- References
- 25
- FWCI
- 8.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.